Drug Profile
Dendritic cell vaccine - Bioclones/AIM ImmunoTech
Alternative Names: Cancer vaccine - Bioclones; Patient-specific DC immunotherapy vaccine - Bioclones/AIM ImmunoTechLatest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Bioclones
- Developer AIM ImmunoTech; Bioclones
- Class Cancer vaccines; Dendritic cell vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Breast cancer; Cancer; Prostate cancer
Most Recent Events
- 23 Aug 2019 Hemispherx Biopharma is now called AIM ImmunoTech
- 28 Aug 2018 No recent reports of development identified for preclinical development in Breast-cancer in South Africa (Parenteral, Injection)
- 28 Aug 2018 No recent reports of development identified for preclinical development in Prostate-cancer in South Africa (Parenteral, Injection)